Zurück zu Ihrem Suchergebnis

Beschreibung

Product Source: Expressed by baculovirus in Sf21 insect cells., N-terminal 6His-tagged recombinant human Abl, residues 27-end containing the Q252H mutation. The Abl tyrosine kinase inhibitor STI571 is an effective therapy for stable-phase chronic myeloid leukemia patients. Many patients responding to STI571 later relapse due to a reactivation of Bcr-Abl activity. In certain cases this appears to correlate with the presence of the Q252H mutation, which confers resistance to drug binding (Shah et al., (2002), Cancer Cell 2, 117-125).